Clinical Trial

Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients

Study acronym: COMPETE
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of the study is to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive, somatostatin receptor-positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET).
Protocol Amendment History 34 amendments
This ClinicalTrials.gov record has been amended 34 times since 2017-02-07; most recent amendment 2026-03-17.
Status change: Recruiting → Active, Not Recruiting 2022-04-11
Trial Details
NCT Number NCT03049189
Lead Sponsor ITM Solucin GmbH
Collaborators: ABX CRO, PSI CRO
Conditions Neuroendocrine Tumors
Enrollment 324 participants
Start Date 2017-02-02
Primary Completion 2024-11-27 (estimated)
Study Completion 2029-11 (estimated)
Updated on ClinicalTrials.gov 2026-08-07